RT Journal Article
SR Electronic
T1 Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20216887
DO 10.1101/2020.10.28.20216887
A1 Sörgel, Fritz
A1 Malin, Jakob J.
A1 Hagmann, Henning
A1 Kinzig, Martina
A1 Bilal, Muhammad
A1 Eichenauer, Dennis A.
A1 Scherf-Clavel, Oliver
A1 Simonis, Alexander
A1 Tabei, Lobna El
A1 Fuhr, Uwe
A1 Rybniker, Jan
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.28.20216887.abstract
AB Remdesivir, a drug with provisional approval for the treatment of COVID-19, is not recommended in patients with an estimated glomerular filtration rate ≤ 30 mL/min. Here we provide a first detailed pharmacokinetic assessment of remdesivir and its major metabolites in a patient with end stage renal disease on hemodialysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee at the university hospital of cologne (Reference: 20-1295)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request